Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals, Inc. filed a Form 13F reporting institutional holdings as of the filing, listing 2 information-table entries with a Form 13F Information Table Value Total of $47,884,476. The report was signed by Leonard Brooks, Senior Vice President, Treasurer, on 05-08-2026.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock in multiple open-market trades on May 1, 2026. The shares were sold at prices generally between about $701 and $714 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025. After these planned sales, he continues to hold a direct equity stake in the company.
Regeneron Pharmaceuticals Inc disclosure: Vanguard Capital Management reported beneficial ownership of 7,660,810 shares of Common Stock, representing 7.37% of the class. The filing shows sole voting power for 1,005,897 shares and sole dispositive power over 7,660,810 shares.
The filing states these holdings include shares held for Vanguard funds and managed accounts and is signed by Vanguard Capital Management's Head of Global Fund Administration on 04/30/2026.
Regeneron Pharmaceuticals reported strong first quarter 2026 results, with total revenues rising 19% to $3.6 billion from $3.0 billion a year earlier, driven by Dupixent and oncology growth. GAAP net income declined 10% to $727 million as higher R&D, IPR&D and manufacturing costs weighed on margins, while non-GAAP net income increased 12% to $1.04 billion and diluted non‑GAAP EPS grew 15% to $9.47.
Dupixent global net sales recorded by Sanofi rose 33% to $4.9 billion, and Libtayo global net sales climbed 54% to $438 million. EYLEA HD U.S. net sales jumped 52% to $468 million, but combined U.S. EYLEA HD and EYLEA net sales fell 10% to $941 million amid competitive pressures and patient transition to EYLEA HD.
The quarter featured multiple regulatory wins, including FDA and EC approvals expanding Dupixent indications, extended EYLEA HD dosing intervals, and accelerated FDA approval of Otarmeni, which Regeneron will provide for free in the U.S. The company repurchased $803 million of stock, authorized a new $3.0 billion buyback, and declared a $0.94 per‑share dividend. Guidance for 2026 largely held, though GAAP gross margin on net product sales was trimmed to 77–78% due to a temporary manufacturing interruption in Ireland.
Regeneron Pharmaceuticals calls a virtual 2026 annual meeting on June 12 for shareholders to elect five directors to one‑year terms, ratify PricewaterhouseCoopers as auditor, and cast an advisory say‑on‑pay vote.
For 2025, Regeneron generated $14.34 billion in revenue, up 1%, with GAAP diluted EPS of $41.48 and non‑GAAP diluted EPS of $44.31. The company invested $5.9 billion in R&D (about 41% of revenue), returned $3.5 billion through share repurchases and initiated a quarterly dividend, and spent nearly $900 million on U.S. research and manufacturing capacity.
The proxy highlights a portfolio of 15 internally developed approved or authorized medicines, including four blockbuster drugs such as Dupixent, EYLEA/EYLEA HD, and Libtayo, and nearly 50 clinical candidates. Governance updates include phasing in annual director elections after declassifying the board, creating a new Digital Technology Committee for AI and cybersecurity oversight, and continued extensive shareholder engagement. The board reports 85% independence and strong meeting attendance, and details a director pay mix tilted toward equity to align with long‑term shareholder value.
Regeneron Pharmaceuticals, Inc. expects to record an acquired in-process research and development charge of approximately $102 million on a pre-tax basis in its first quarter 2026 results. This stems mainly from premiums on equity securities and development milestone and up-front payments tied to collaboration and licensing agreements.
The company expects this acquired IPR&D charge to reduce both GAAP and non-GAAP net income per diluted share for the first quarter 2026 by approximately $0.81. These figures are preliminary, unaudited estimates and remain subject to completion of Regeneron’s financial statement closing procedures.
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of Common Stock in open-market transactions. The sales occurred on April 1, 2026 at prices ranging from about $771.32 to $779.71, executed in multiple small tranches using volume-weighted average prices.
The filing states these dispositions were made under a pre-arranged trading plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Following the transactions, Ryan directly holds 17,603 Common Stock shares of Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc — Amendment No. 7 to a Schedule 13G/A filed by The Vanguard Group reports 0 shares beneficially owned and 0% of the common stock. The filing states Vanguard completed an internal realignment on January 12, 2026, and certain subsidiaries will report disaggregated holdings under SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It notes Vanguard and related investment vehicles retain the right to dividends or proceeds where applicable but that no single external person holds more than 5% of the class in the reported holdings.